A worldwide quest is under way to find new treatments to stop, slow or even prevent Alzheimer’s disease. Because new drugs take years to produce from concept to market — and because drugs that seem promising in early-stage studies may not work as hoped in large-scale trials — it is critical that Alzheimer’s and other dementia research continues to accelerate. To advance this effort, the Alzheimer’s Association funds researchers looking at new treatment strategies and advocates for more federal funding of Alzheimer’s research.
Currently, there are five Alzheimer’s drugs approved by the U.S. Food and Drug Administration (FDA) that treat the symptoms of Alzheimer’s disease — temporarily helping memory and thinking problems — with a sixth drug available globally. However, these medications do not treat the underlying causes of the disease or slow its progression.
Many drugs in development aim to interrupt the disease process itself by impacting one or more of the brain changes associated with Alzheimer’s. These changes offer potential targets for new drugs to slow or stop the progress of the disease. Researchers believe successful treatment will eventually involve a combination of medications aimed at several targets, similar to current treatments for many cancers and AIDS.
The following are examples of promising targets for next-generation drug therapies under investigation in current research studies:
Beta-amyloid is the chief component of plaques, one hallmark Alzheimer’s brain abnormality. Scientists have a detailed understanding of how this protein fragment is clipped from its parent compound, amyloid precursor protein (APP), by two enzymes — beta-secretase and gamma-secretase — to form the beta-amyloid protein that is present in abnormally high levels in the brains of people living with Alzheimer’s. Researchers are developing medications aimed at almost every point in the amyloid processing pathway. This includes blocking activity of the beta-secretase enzyme; preventing the beta-amyloid fragments from clumping into plaques; and using antibodies against beta-amyloid to clear it from the brain. Several clinical trials of investigational drugs targeting beta-amyloid are underway.
Current drugs in research that targets beta-amyloid: CAD106 and CNP520
Two anti-amyloid compounds – CAD106, an active immunotherapy, and CNP520 – are being studied to determine if they can prevent or delay the emergence of symptoms of Alzheimer’s among higher-risk cognitively healthy older adults who have two copies of the e4 type of the APOE gene, one from each parent. The two studies, known as the Alzheimer’s Prevention Initiative (API) Generation Study 1 and Generation Study 2, will determine whether the drugs can combat the accumulation of the protein fragment beta-amyloid into the amyloid plaques that are a hallmark of Alzheimer’s. Plaques form between nerve cells (neurons) in the brain and interfere the with neuron-to-neuron communication that enables the brain to store new information. The studies are expected to conclude in 2025.
One of the enzymes that clips APP, BACE makes it possible for beta-amyloid to form. Therapies that interrupt this process may reduce the amount of beta-amyloid in the brain and ultimately intervene in the development of Alzheimer’s disease.
Current drug in research that targets beta-secretase: JNJ-54861911.
JNJ-54861911 inhibits the ability of the beta-secretase enzyme to make beta-amyloid. It is currently in a Phase 3 study to determine if it slows cognitive decline in people who do not have Alzheimer’s symptoms but have elevated levels of beta-amyloid in the brain. The study is expected to be completed in 2024. JNJ-54861911 is administered in pill form. (Drug is still in research; not available to the public.)
Tau protein is the chief component of tangles, the other hallmark brain abnormality of Alzheimer’s disease. Tau protein helps maintain the structure of a neuron, including tiny tube-like structures called microtubules that deliver nutrients throughout the neuron. Researchers are investigating mechanisms to prevent tau protein from collapsing and twisting into tangles, a process that destroys microtubules and, ultimately, the neuron itself.
Current drug in research that targets tau protein: AADvac1
AADvac1 is a vaccine that stimulates the body’s immune system to attack an abnormal form of tau protein that destabilizes the structure of neurons. If successful, it has the potential to help stop the progression of Alzheimer’s disease. A Phase 2 clinical trial, called ADAMANT, enrolled 208 volunteers living with mild Alzheimer’s disease began in March 2016 and was completed in June 2019. Initial results were announced in September 2019 and showed that 98.2% of participants who were given the vaccine generated antibodies to the tau protein. The results also showed no difference in adverse events between the treatment and control groups, meaning that the treatment was well tolerated. The change in several biomarkers for Alzheimer’s disease showed trends that suggest AADvac1 may slow the progression of the disease. The slowing of the progression was also supported by positive changes in several cognitive endpoints. Based on the results, the vaccine will continue to be studied in the next level of clinical trials. (Drug is still in research; not available to the public.)
Inflammation in the brain has long been known to play a role in the changes that occur in Alzheimer’s disease. Both beta-amyloid plaques and tau tangles cause an immune response in the brain, and microglia cells act as the first form of immune defense against them. However, while microglia help clear beta-amyloid in the brain, they can become overactive in the presence of plaques and produce compounds that damage nearby cells.
Current drug in research that targets inflammation: Sargramostim
Approved by the FDA for bone marrow stimulation in people with leukemia, Sargramostim stimulates the innate immune system. It is being tested in Alzheimer’s because it may stimulate immune processes that could protect neurons in the brain from toxic proteins. A Phase 2 study of Sargramostim is underway. It is expected to be completed in May 2020. (Drug is still in research; not available to the public.)
The 5HT6 receptor found on some brain cells can lock in chemicals called neurotransmitters. This decreases the amount of neurotransmitters available for the brain to use for communication between nerve cells (neurons). Only through neuron-to-neuron communication can an individual think and function normally. Acetylcholine is one of these neurotransmitters. People living with Alzheimer’s disease have low levels of acetylcholine. Blocking the 5HT6 receptor may increase the amount of acetylcholine and help nerve cells to maintain normal communication.
Current drug in research that targets 5-HT2A: Pimavanserin
Pimavanserin is an inverse agonist for the 5-HT2A receptor. This means that pimavanserin mimics the shape of the serotonin “key” and fits into the 5-HT2A “lock.” However, pimavanserin has the opposite effect of serotonin: it reduces communication between neurons. This may have the effect of reducing the symptoms of dementia-related psychosis. A Phase 3 clinical trial of pimavanserin, called the HARMONY study, met the primary endpoint of the study and was stopped at the preplanned interim analysis by significantly reducing risk of relapse of psychosis by 2.8-fold compared with placebo. The company studying the drug plans to meet with the U.S. Food and Drug Administration (FDA) in the first half of 2020 regarding a supplemental new drug application submission. The FDA previously granted Breakthrough Therapy designation for pimavanserin for the treatment of dementia-related psychosis. Currently, no drug is specifically approved for this indication. (Drug is still in research; not available to the public.)
Copyright © 2021 The Waters of Indianapolis - All rights reserved.